LYRA Stock Analysis: Buy, Sell, or Hold?
LYRA - Lyra Therapeutics, Inc. Common Stock
$1.78
-0.26 (-12.75%)
▼
WAIT
LOW Confidence
Last Updated: January 30, 2026
Earnings: Mar 12, 2026
Get Alerted When LYRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: LYRA is down 13.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: LYRA is down 13.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: LYRA is currently trading at $1.78, which is considered oversold relative to its 30-day fair value range of $1.89 to $3.38.
Technical Outlook: Technically, LYRA is in a strong downtrend. Immediate support is located at $1.60, while resistance sits at $2.58. Short-term momentum is weak, with the stock down 12.7% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.50 (+546.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LYRA is in a strong downtrend. Immediate support is located at $1.60, while resistance sits at $2.58. Short-term momentum is weak, with the stock down 12.7% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.50 (+546.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$1.89 -
$3.38
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
Protect Your Profits
Holding LYRA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-12.7%)
- BULLISH: Trading 546.1% below Wall St target ($11.50)
- WARNING: Recommendation downgraded due to -13.2% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$1.89 -
$3.38
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$1.60
Resistance Level
$2.58
Current Trend
Strong Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
-0.25
Wall Street Target
$11.50
(+546.1%)
Revenue Growth (YoY)
-87.2%
Last updated: February 01, 2026 6:52 AM ET
Data refreshes hourly during market hours. Next update: 7:52 AM
Data refreshes hourly during market hours. Next update: 7:52 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LYRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 59 HOLD |
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$22 | 60 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$117 | 59 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$141 | 59 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |
Advanced LYRA Option Strategies
Professional options setups generated by AI based on today's LYRA price and gamma walls.
